Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, discusses how closed-loop artificial pancreas systems can help reduce the burden of type 1 diabetes (T1D) management during pregnancy.
Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, discusses the risks associated with hypoglycemia and hyperglycemia in pregnant patients with type 1 diabetes (T1D), as well as how a closed-loop insulin delivery system, or artificial pancreas, can help reduce the burden of T1D management during pregnancy.
Levister and colleagues at Mount Sinai have collaborated with other institutions to customize an artificial pancreas system for pregnant patients with T1D, who have tighter glucose targets compared with people with T1D who are not pregnant. Clinical trials were conducted by a consortium including Mount Sinai; Mayo Clinic in Rochester, Minnesota; and the Sansum Diabetes Research Institute in Santa Barbara, California.
Transcript
What are the risks associated with managing type 1 diabetes in pregnancy, and how are these addressed in a closed-loop system?
Because the glucose targets during pregnancy are tighter and on the lower side compared to those outside of pregnancy, there is a risk for hypoglycemia, or low blood sugar, when you have a system that's being more aggressive in terms of managing glucose and keeping it on the lower side as opposed to higher. One of the concerns that you have—not just with a closed-loop system, but when a woman is managing diabetes, either with injections or a insulin pump that is not part of a closed-loop system, or artificial pancreas system—is you have concern for severe low blood sugars that can lead to loss of consciousness or seizure. This was also a concern that we had for our participants in the study.
One of the things about a closed-loop system is that it can decrease, or stop, insulin delivery when the glucose was predicted to go below a certain level, and that will help with preventing hypoglycemia. This can still occur, but we did see a reduction in hypoglycemia in those that use the system compared to prior when they were not using the system.
A few of the concerns in regards to hyperglycemia during pregnancy are preeclampsia for the mother, medically indicated preterm delivery for the unborn child. You have risk for the child being born large for gestational age, which increases the need for cesarean section. And for those that are vaginally delivered, you have a higher risk for something called shoulder dystocia, where the shoulder can get caught in the birth canal during delivery and cause trauma to the child. You also have concerns for things like fetal death for placental malfunction and for delayed lung maturity. Those are all concerns that we have. That's one of the things that's driving us to help these patients to have an increased percent of time within target range to help prevent those complications from occurring.
And of course, the other thing that we want to do is, we want to help to relieve the patient's burden. You're always going to be thinking about glucoses and the safety of your baby during pregnancy with type 1 diabetes—I think that's something that we can't get rid of. But if a patient has the sense that they have a system that they're working with that can prevent them from having severe low blood sugars, potentially that can reduce their risk of having really high blood sugars, maybe it allows them to have a little less burden in regard to the both emotional impact and then just the day-to-day impact in regard to management. Maybe it allows them to partake in activities that they wouldn't usually partake in because they'd have concerns about it—and also just get a better night's sleep because they don't have as many concerns about running really high overnight or running really low overnight.
Reference
Levy CJ, Kudva YC, Ozaslan B, et al. At-home use of a pregnancy-specific zone-MPC closed-loop system for pregnancies complicated by type 1 diabetes: a single-arm, observational multicenter study. Diabetes Care. 2023;46(7):1425-1431. doi:10.2337/dc23-0173
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More